NEW YORK, April 15, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Performance Sports Group Ltd. (“PSG” or the “Company”) (NYSE:PSG) between August 27, 2015 and March 7, 2016.
You are hereby notified that a securities class action has been commenced in the USDC for the Central District of California, Western Division. If you purchased or otherwise acquired PSG securities between August 27, 2015 and March 7, 2016, your rights may be affected by this action. To get more information go to: http://www.zlk.com/pslra/performance-sports-group.
The lawsuit concerns allegations that the Company and its executives violated federal securities laws by failing to disclose the financial pressures on the Company due to Sports Authority’s financial decline and the fall in demand in the softball, baseball and hockey markets.
If you suffered a loss in PSG you have until May 17, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://www.zlk.com/pslra/performance-sports-group.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Eduard Korsinsky, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
FDA Approves Mitapivat for Anemia in Thalassemia Patients
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Italy Fines Apple €98.6 Million Over App Store Dominance
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 



